RuthMO'ReganMD

Oncology • Rochester, NY

Breast Cancer

Professor and Chair of Medicine

Join to view full profile

Dr. O'Regan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. O'Regan's full profile

Already have an account?

Office
601 Elmwood Ave
Rochester, NY 14642
Phone+1 585-275-7938

Fax+1 585-486-0649

Education & Training

McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1998 - 1999
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1995 - 1998
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 1994 - 1995
University College of Dublin National Univ SOMClass of 1988

Certifications & Licensure

NY State Medical License 2021 - 2026
WI State Medical License 2015 - 2025
GA State Medical License 2003 - 2017
IL State Medical License 1995 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Atlanta Magazine: Top Doctors Castle Connolly, 2007, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013

Clinical Trials

Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer Start of enrollment: 2006 Dec 01
Unknown status
Phase 2
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores Start of enrollment: 2009 Apr 01
Terminated
Phase 2
Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer Start of enrollment: 2009 May 01
Completed
Phase 2
Re-expression of ER in Triple Negative Breast Cancers Start of enrollment: 2010 Jul 01
Terminated
Phase 1, Phase 2
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer Start of enrollment: 2016 Mar 01
Active, not recruiting
Phase 2
Ribociclib and Bicalutamide in AR+ TNBC Start of enrollment: 2018 May 07
Recruiting
Phase 1, Phase 2
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer Start of enrollment: 2018 Nov 13
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

314 citations
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
Mary Jo Lund, Katrina F. Trivers, Peggy L. Porter, Ralph J. Coates, Brian Leyland-Jones
Breast Cancer Research and Treatment. 2009-01-01
384 citations
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Benjamin O Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese
Journal of the National Comprehensive Cancer Network. 2020-04-01
355 citations
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.
Elisavet Paplomata, Ruth O'Regan
Therapeutic Advances in Medical Oncology. 2014-04-01

Lectures

Evolving Approaches in Systemic Therapy for Triple-Negative Breast Cancer in Neoadjuvant and Adjuvant Settings.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Study TTC-352-101: Phase 1 study of TTC-352 in patients with metastatic breast cancer (BC) progressing on endocrine therapy.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Assay Predicts Breast Cancer Patients Who Will Benefit from Ovarian SuppressionDecember 7th, 2022
New Options for Metastatic HER2-Positive Breast CancerJanuary 18th, 2022
Using Genomic Profiling to Select the Right Therapy for Metastatic Breast CancerJanuary 11th, 2022
Join now to see all